Ares Trading S.a.

Applied Research Systems Ars Holding N.v.

Yeda Research and Develpment & Co. Ltd

Laboratoires Serono S.a.

Merck Serono S. a.

Ursula Boschert

Christine Power

Yolande Chvatchko

Richard Fagan

Christopher Benjamin Phelps

Georg Feger

Ruben Papoian

Raghuram Selvaraju

Lilia Bernasconi

Andrew Robert Davids

Michel Revel

Judith Chebath

Richard James Mitter

Marina Pizzi

PierFranco Spano

This invention relates to novel uses of a protein sequence (INSP052EC), herein identified as an immunoglobulin domain-containing cell surface recognition, in the diagnosis, prevention and treatment of diseases, in particular those related to the excessive expression and/or secretion of cytokines.

Method of treatment comprising administration of a cytokine antagonist molecule

This invention relates to a novel protein (INSP052), herein identified as an immunoglobulin domain-containing cell surface recognition molecule and to the use of this proteins and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease. The invention also relates to the identification of the extracellular domain of INSP052.

Cytokine antagonist molecules

This invention relates to proteins termed INSP005and INSP005, herein identified as secreted proteins, in particular members of the metalloprotease family and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention, and treatment of disease.

Metalloprotease proteins

The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.

Use of osteopontin for the treatment and/or prevention of neurologic diseases

The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

IL6RIL6 chimera for the treatment of neurodegenerative diseases

Growing community of inventors

Troinex, Switzerland

Ursula Boschert